Omnicell Inc (OMCL) valuation against sector peers: P/E 38.5 (sector median 30.9), P/B 1.3, EV/EBIT 24.3, free-cash-flow yield 8.5%, P/S 1.4.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Metric	OMCL	Sector median	vs median
P/E	38.5	30.9 · n=159	24% above
P/B	1.3	4.0 · n=307	67% below
P/S	1.4	4.1 · n=299	67% below
EV/EBIT	24.3	25.6 · n=146	5% below
Free-cash-flow yield	8.5%	1.4% · n=288	487% above
Dividend yield	0.00%	0.00% · n=362	—
Return on equity	3.5%	−2.1% · n=308	—
Return on invested capital	3.6%	0.6% · n=282	460% above
Gross margin	45.1%	63.3% · n=205	29% below
Net debt / EBITDA	−1.04	1.27 · n=151	182% below

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Value factor: 95 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

Instrument	P/E	P/B	EV/EBIT	Free-cash-flow yield	Dividend yield	Smart Score
LLYEli Lilly & Co	48.2	33.0	—	1.5%	0.6%	6/10
JNJJohnson & Johnson	42.2	8.3	—	3.0%	1.9%	8/10
ABBVAbbVie	50.3	—	27.7	3.6%	2.9%	6/10
MRKMerck	149.5	8.2	—	4.0%	2.3%	8/10
UNHUnitedHealth	22.4	3.4	17.1	6.4%	2.3%	10/10
TMOThermo Fisher Scientific	37.8	4.9	35.7	2.8%	0.3%	9/10
AMGNAmgen	26.8	17.5	23.2	3.8%	2.1%	8/10
GILDGilead Sciences	—	16.1	—	6.6%	1.9%	5/10
ABTAbbott	40.7	3.8	32.9	3.5%	2.8%	6/10
PFEPfizer	41.3	1.9	—	7.1%	7.4%	1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 04 Nov 2026

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.

Cookie settings